Abstract
Several research groups have begun to associate the Alzheimer Disease (AD) to Diabetes Mellitus (DM), obesity and cardiovascular disease. This relationship is so close that some authors have defined Alzheimer Disease as Type 3 Diabetes. Numerous studies have shown that people with type 2 diabetes have twice the incidence of sporadic AD.
Insulin deficiency or insulin resistance facilitates cerebral β-amyloidogenesis in murine model of AD, accompanied by a significant elevation in APP (Amyloid Precursor Protein) and BACE1 (β-site APP Cleaving Enzime 1). Similarly, deposits of Aβ produce a loss of neuronal surface insulin receptors and directly interfere with the insulin signaling pathway. Furthermore, as it is well known, these disorders are both associated to an increased cardiovascular risk and an altered cholesterol metabolism, so we have analyzed several therapies which recently have been suggested as a remedy to treat together AD and DM.
The aim of the present review is to better understand the strengths and drawbacks of these therapies.
Keywords: Type 2 Diabetes, Alzheimer's disease, Statins, Liraglutide, Metformin
Current Diabetes Reviews
Title:Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Volume: 9 Issue: 3
Author(s): Arianna Vignini, Alessia Giulietti, Laura Nanetti, Francesca Raffaelli, Lucia Giusti, Laura Mazzanti and Leandro Provinciali
Affiliation:
Keywords: Type 2 Diabetes, Alzheimer's disease, Statins, Liraglutide, Metformin
Abstract: Several research groups have begun to associate the Alzheimer Disease (AD) to Diabetes Mellitus (DM), obesity and cardiovascular disease. This relationship is so close that some authors have defined Alzheimer Disease as Type 3 Diabetes. Numerous studies have shown that people with type 2 diabetes have twice the incidence of sporadic AD.
Insulin deficiency or insulin resistance facilitates cerebral β-amyloidogenesis in murine model of AD, accompanied by a significant elevation in APP (Amyloid Precursor Protein) and BACE1 (β-site APP Cleaving Enzime 1). Similarly, deposits of Aβ produce a loss of neuronal surface insulin receptors and directly interfere with the insulin signaling pathway. Furthermore, as it is well known, these disorders are both associated to an increased cardiovascular risk and an altered cholesterol metabolism, so we have analyzed several therapies which recently have been suggested as a remedy to treat together AD and DM.
The aim of the present review is to better understand the strengths and drawbacks of these therapies.
Export Options
About this article
Cite this article as:
Vignini Arianna, Giulietti Alessia, Nanetti Laura, Raffaelli Francesca, Giusti Lucia, Mazzanti Laura and Provinciali Leandro, Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies, Current Diabetes Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573399811309030003
DOI https://dx.doi.org/10.2174/1573399811309030003 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ganoderma lucidum: A Potent Pharmacological Macrofungus
Current Pharmaceutical Biotechnology Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Statins in Diabetes Mellitus
Current Pharmaceutical Design Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Ambulatory Blood Pressure Monitoring in Prehypertensive Subjects
Cardiovascular & Hematological Disorders-Drug Targets Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Phenolic Compounds, Antioxidant Properties and Enzyme Inhibition Ability of Adiantum capillus veneris L. linked to Alzheimer’s Disease, Diabetes Mellitus and Skin Disorders
Current Organic Chemistry The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Developmental Changes in the Roles of Patients and Families in Type 1 Diabetes Management
Current Diabetes Reviews Anti-Proliferative Activity of Standardized Methanol Extract of Coscinium fenestratum and Its Major Constituent, Berberine, Against Nasopharyngeal Carcinoma Cells
The Natural Products Journal Development of Novel Glitazones as Antidiabetic Agents: Molecular Design, Synthesis, Evaluation of Glucose Uptake Activity and SAR Studies
Letters in Drug Design & Discovery Impaired Glycogen Synthase Activity and Mitochondrial Dysfunction in Skeletal Muscle: Markers or Mediators of Insulin Resistance in Type 2 Diabetes?
Current Diabetes Reviews Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Current Topics in Medicinal Chemistry Screening GLP-1 Receptor Ligands from Natural Products in Herbs through High-Content Technique
Combinatorial Chemistry & High Throughput Screening The Concept of Titration can be Transposed to Fluid Management. But does is Change the Volumes? Randomised Trial on Pleth Variability Index During Fast-Track Colonic Surgery
Current Clinical Pharmacology Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery Coupling Classical Analytical Methods with Modeling in Routine Analysis Tests - Merits and Drawbacks
Current Analytical Chemistry